LIMBIX

Limbix Presents Data Demonstrating Treatment with SparkRx Digital Therapeutic Results in Clinically Meaningful Reductions in Depressive Symptoms in Adolescents

Retrieved on: 
Friday, October 8, 2021
Software, Teens, Health, Mental Health, Children, Technology, Consumer, Mobile, Wireless, Mindfulness, Mental health, Digital therapeutics, Trial of the century, Adolescence, Digital, Conference, Signs and symptoms, COVID-19, Food, Program, Safety, Smartphone, FDA, Child, Depression, Problem solving, Grammatical mood, American Academy, Therapy, Â, Ageing, Anxiety, Policy, Patient, Clinical trial, Psychology, Pharmaceutical industry, Medicine, the Clinical Trial, SparkRx, Limbix, THE CLINICAL TRIAL, SPARKRX, LIMBIX

Today, Limbix , a prescription digital therapeutic company developing mental health treatments for adolescents, announced positive results from a virtual randomized controlled trial of SparkRx , the companys digital therapeutic for adolescents with symptoms of depression.

Key Points: 
  • Today, Limbix , a prescription digital therapeutic company developing mental health treatments for adolescents, announced positive results from a virtual randomized controlled trial of SparkRx , the companys digital therapeutic for adolescents with symptoms of depression.
  • Across the full study sample of 121 participants with moderate to severe depressive symptoms, adolescents randomized to SparkRx showed a clinically meaningful reduction in depression symptoms.
  • Limbix SparkRx is a cognitive behavioral therapy-based digital therapeutic program for teens and young adults experiencing symptoms of depression.
  • Their first digital therapeutic, Limbix SparkRx, is now available for licensed health care professionals to offer to patients nationwide.

Limbix Launches First Digital Therapeutic for Adolescents with Symptoms of Depression

Retrieved on: 
Friday, October 8, 2021
Other Health, Software, Mobile, Wireless, Family, Consumer, Mental Health, Technology, Teens, Parenting, Children, Clinical Trials, Health, Mindfulness, Mental health, Pediatrics, Cognitive behavioral therapy, Behavior, Adolescence, Conference, COVID-19, Food, Program, Safety, Smartphone, FDA, Depression, Problem solving, Behavioral activation, Grammatical mood, American Academy, Therapy, Ageing, Policy, Patient, Clinical trial, Psychology, Pharmaceutical industry, Toy, Medicine, SparkRx, Limbix, SPARKRX, LIMBIX

Today, Limbix , a prescription digital therapeutic company developing mental health treatments for adolescents, announced the launch of SparkRx , the first evidence-based digital therapeutic for teens and young adults experiencing symptoms of depression.

Key Points: 
  • Today, Limbix , a prescription digital therapeutic company developing mental health treatments for adolescents, announced the launch of SparkRx , the first evidence-based digital therapeutic for teens and young adults experiencing symptoms of depression.
  • Limbix SparkRx is a cognitive behavioral therapy-based digital therapeutic program for teens and young adults experiencing symptoms of depression.
  • Limbix is a prescription digital therapeutic company passionate about creating mental health treatments for adolescents.
  • Their first digital therapeutic, Limbix SparkRx, is now available for licensed health care professionals to offer to patients nationwide.

Limbix to Present Efficacy Data From SparkRx Digital Therapeutic Clinical Trial in Adolescents With Moderate to Severe Depressive Symptoms at 2021 American Academy of Pediatrics National Conference & Exhibition Virtual Experience

Retrieved on: 
Monday, October 4, 2021
Mental Health, Health, Medical Devices, Technology, Mobile, Wireless, Software, Clinical Trials, American Academy of Pediatrics, Therapy, Policy, Cognitive behavioral therapy, Psychology, National Conference, Smartphone, Clinical Information Technology Program Office, Conference, Depression, Patient, Adolescence, Mindfulness, Public health, Problem solving, American Academy, Grammatical mood, AAP, Mental health, COVID-19, Safety, Pharmaceutical industry, SparkRx, Limbix, SPARKRX, LIMBIX

Limbix , a prescription digital therapeutic company developing mental health treatments for adolescents, today announced Benjamin Alouf, M.D., chief medical officer of Limbix, will present clinical data demonstrating the efficacy of SparkRx in adolescents with moderate to severe depressive symptoms at the upcoming American Academy of Pediatrics (AAP) National Conference.

Key Points: 
  • Limbix , a prescription digital therapeutic company developing mental health treatments for adolescents, today announced Benjamin Alouf, M.D., chief medical officer of Limbix, will present clinical data demonstrating the efficacy of SparkRx in adolescents with moderate to severe depressive symptoms at the upcoming American Academy of Pediatrics (AAP) National Conference.
  • SparkRx is a digital therapeutic rooted in cognitive behavioral therapy, a proven therapeutic modality to assist with the symptoms of depression and other mental health disorders.
  • Limbix SparkRx is a cognitive behavioral therapy-based digital therapeutic program for teens and young adults experiencing symptoms of depression.
  • Their first digital therapeutic, Limbix SparkRx, will be available soon for licensed healthcare professionals to offer to patients nationwide.